We invite you to explore the recent article “Next Level Biopharmaceuticals” featured in the Business Focus Magazine’s latest issue. Business Focus Magazine interviewed Biovian’s CEO and co-founder Antti Nieminen about Biovian’s growth story and position …
Biovian, a biopharmaceutical CDMO providing One-Stop-Shop GMP services to a global client base, is delighted to announce the appointment of Jayme Tortorici, based in San Diego, CA, as its new Business Development Director. Jayme Tortorici …
The article discusses the reasons behind the growing need for viral vectors and how Biovian, as a CDMO has taken actions to solve the manufacturing bottleneck. Antti Nieminen, CEO of Biovian: “The majority of Biovian’s customers …
Biovian’s client satisfaction survey was conducted in November using Net Promoter Score (NPS) survey. The score of 67 puts Biovian into the category “Excellent” based on the creators of NPS, Bain & Co. Flexibility, good …
Biovian received a new automated filling line right before Christmas in 2020 from Optima packaging group. This article describes the project from the planning phase until the assembly of the filling line. The project is …
Biovian and Lokon Pharma are featured in Biopharma Dealmakers September issue. The article “Manufacturing the next generation of cancer immunotherapeutics”, describes the history and currents state of Lokon Pharma’s proprietary LOAd technology. This immunostimulatory gene …
GEN, one of the biggest magazines in the field of genetic engineering and biotechnology, discussed with four experts how the relationship between a CDMO and a technology provider can accelerate the transition from academia to …
The leading regional newspaper of of the Southwest Finland interviewed Knut Ringbom, the CEO of Biovian about the COVID-19 vaccine manufacturing possibilities. “Pandemic vaccine manufacturing is a hot topic. We have been contacted by European …
GEN, one of the biggest biotech magazines interviewed Biovian about the critical bottlenecks in Adeno-associated virus (AAV) Manufacturing. AAVs, gene therapy and manufacturing technologies are two of the “hottest” biotech areas in the industry right …
Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely critical. In this roundtable discussion, …
